Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Repeated dose toxicity: inhalation

Currently viewing:

Administrative data

Endpoint:
short-term repeated dose toxicity: inhalation
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)

Data source

Reference
Reference Type:
publication
Title:
Full Public Report Sodium Ethyl Xanthate Priority Existing Chemical No. 5
Author:
Australian Government Publishing Service Canberra
Year:
1995
Bibliographic source:
Australian Government Publishing Service Canberra

Materials and methods

Test guideline
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 412 (Subacute Inhalation Toxicity: 28-Day Study)
GLP compliance:
not specified

Test material

Constituent 1
Reference substance name:
Potassium O-pentyl dithiocarbonate
EC Number:
220-329-5
EC Name:
Potassium O-pentyl dithiocarbonate
Cas Number:
2720-73-2
IUPAC Name:
potassium O-pentyl dithiocarbonate
Constituent 2
Reference substance name:
Potassium amyl xanthate
IUPAC Name:
Potassium amyl xanthate
Test material form:
aerosol dispenser: not specified
Remarks:
migrated information: aerosol

Test animals

Species:
mouse
Strain:
Swiss Webster
Sex:
male

Administration / exposure

Route of administration:
inhalation: aerosol
Type of inhalation exposure:
whole body
Vehicle:
air
Analytical verification of doses or concentrations:
yes
Duration of treatment / exposure:
30-day
Frequency of treatment:
6 hrs daily, 5 days a week for a total of 20 exposures in 1 month
Doses / concentrationsopen allclose all
Remarks:
Doses / Concentrations:
100 mg/m3
Basis:
nominal conc.
Remarks:
Doses / Concentrations:
800 mg/m3
Basis:
nominal conc.
No. of animals per sex per dose:
10

Results and discussion

Results of examinations

Clinical signs:
effects observed, treatment-related
Description (incidence and severity):
10 from the original group and 5/6 replacement animals died. Convulsions hyperactivity in 5/16 prior to death.
Mortality:
mortality observed, treatment-related
Description (incidence):
10 from the original group and 5/6 replacement animals died. Convulsions hyperactivity in 5/16 prior to death.
Body weight and weight changes:
no effects observed
Description (incidence and severity):
No change
Organ weight findings including organ / body weight ratios:
effects observed, treatment-related
Description (incidence and severity):
Higher liver to body weight ratio than controls. Higher absolute liver weight
Histopathological findings: non-neoplastic:
no effects observed
Description (incidence and severity):
No changes

Effect levels

open allclose all
Dose descriptor:
NOAEC
Effect level:
100 mg/m³ air (analytical)
Based on:
test mat.
Sex:
male
Basis for effect level:
other: Higher liver to body weight ratio than controls. No treatment related change
Dose descriptor:
LOAEC
Effect level:
800 mg/m³ air (analytical)
Based on:
test mat.
Sex:
male
Basis for effect level:
other: Higher liver to body weight ratio than controls ratio than controls. Higher absolute liver weight. 10 from the original group and 5/6 replacement animals died. Convulsions hyperactivity in 5/16 prior to death.

Target system / organ toxicity

Critical effects observed:
not specified

Applicant's summary and conclusion

Conclusions:
The results of this study indicate that potassium amyl xanthate has an adverse effect on the central nervous system and liver in mice. There were no treatment-related changes in the
haematological or urinalysis values in any of the animals.